(LVTX) – Company Press Releases
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
-
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
-
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
-
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
-
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
-
LAVA Announces Annual Meeting of Shareholders
-
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
-
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
-
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
-
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
-
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
-
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
-
LAVA Therapeutics Announces Appointment of New Directors to the Board
-
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
-
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
-
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
-
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
-
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
-
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
-
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
-
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
-
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
-
LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results
-
LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients
-
LAVA Therapeutics Announces Two Appointments to its Board of Directors
-
LAVA Therapeutics to Participate at the Jefferies Healthcare Conference
-
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical O
-
LAVA Therapeutics Announces Annual Meeting of Shareholders
-
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
-
LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies
-
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
-
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
-
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
-
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
-
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
-
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
-
LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
-
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
-
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
-
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
-
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
-
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
-
LAVA Therapeutics Expands Management Team with Three Key Appointments
-
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
-
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
Back to LVTX Stock Lookup
